PMID- 33942495
OWN - NLM
STAT- MEDLINE
DCOM- 20211018
LR  - 20230124
IS  - 1600-6143 (Electronic)
IS  - 1600-6135 (Linking)
VI  - 21
IP  - 10
DP  - 2021 Oct
TI  - Successful treatment of Epstein-Barr virus-associated primary central nervous 
      system lymphoma due to post-transplantation lymphoproliferative disorder, with 
      ibrutinib and third-party Epstein-Barr virus-specific T cells.
PG  - 3465-3471
LID - 10.1111/ajt.16628 [doi]
AB  - Primary central nervous system lymphoma (PCNSL) occurring following organ 
      transplantation (post-transplantation lymphoproliferative disorder [PTLD]) is a 
      highly aggressive non-Hodgkin lymphoma. It is typically treated with high-dose 
      methotrexate-based regimens. Outcomes are dismal and clinical trials are lacking. 
      It is almost always Epstein-Barr virus (EBV) associated. Two patients (CA1-2) 
      presented with EBV-associated PCNSL after renal transplant. CA1 was on 
      hemodialysis and had prior disseminated cryptococcus and pseudomonas 
      bronchiectasis, precluding treatment with methotrexate. CA2 was refractory to 
      methotrexate. Both were treated off-label with the first-generation Bruton's 
      tyrosine kinase inhibitor ibrutinib for 12 months. Cerebrospinal fluid 
      penetration at therapeutic levels was confirmed in CA1 despite hemodialysis. Both 
      patients entered remission by 2 months. Sequencing confirmed absence of genetic 
      aberrations in human leukocyte antigen (HLA) class I/II and 
      antigen-presentation/processing genes, indicating retention of the ability to 
      present EBV-antigens. Between Weeks 10 and 13, they received third-party 
      EBV-specific T cells for consolidation with no adverse effects. They remain in 
      remission >/=34 months since therapy began. The strength of these findings led to 
      an ongoing phase I study (ACTRN12618001541291).
CI  - (c) 2021 The American Society of Transplantation and the American Society of 
      Transplant Surgeons.
FAU - Law, Soi C
AU  - Law SC
AUID- ORCID: 0000-0002-0782-6951
AD  - Mater Research Institute, The University of Queensland, Brisbane, QLD, Australia.
FAU - Hoang, Thanh
AU  - Hoang T
AD  - Diamantina Institute, The University of Queensland, Brisbane, QLD, Australia.
AD  - Hue University of Medicine and Pharmacy, Hue, Vietnam.
FAU - O'Rourke, Kacey
AU  - O'Rourke K
AD  - Mater Research Institute, The University of Queensland, Brisbane, QLD, Australia.
FAU - Tobin, Joshua W D
AU  - Tobin JWD
AUID- ORCID: 0000-0003-4982-525X
AD  - Mater Research Institute, The University of Queensland, Brisbane, QLD, Australia.
FAU - Gunawardana, Jay
AU  - Gunawardana J
AUID- ORCID: 0000-0003-2695-3849
AD  - Mater Research Institute, The University of Queensland, Brisbane, QLD, Australia.
FAU - Loo-Oey, Dorothy
AU  - Loo-Oey D
AD  - Proteomics Core Facility, Translational Research Institute, Woolloongabba, QLD, 
      Australia.
FAU - Bednarska, Karolina
AU  - Bednarska K
AUID- ORCID: 0000-0001-7201-5269
AD  - Mater Research Institute, The University of Queensland, Brisbane, QLD, Australia.
FAU - Merida de Long, Lilia
AU  - Merida de Long L
AUID- ORCID: 0000-0002-6989-8424
AD  - Mater Research Institute, The University of Queensland, Brisbane, QLD, Australia.
FAU - Sabdia, Muhammed B
AU  - Sabdia MB
AUID- ORCID: 0000-0003-1977-8878
AD  - Mater Research Institute, The University of Queensland, Brisbane, QLD, Australia.
FAU - Hapgood, Greg
AU  - Hapgood G
AUID- ORCID: 0000-0002-7980-8496
AD  - Haematology, Princess Alexandra Hospital, Woolloongabba, QLD, Australia.
FAU - Blyth, Emily
AU  - Blyth E
AUID- ORCID: 0000-0002-7849-7139
AD  - Westmead Institute for Medical Research, University of Sydney, Sydney, NSW, 
      Australia.
FAU - Clancy, Leighton
AU  - Clancy L
AD  - Cellular Therapies, NSW Government Health Pathology, Westmead, NSW, Australia.
FAU - Hennig, Stefanie
AU  - Hennig S
AUID- ORCID: 0000-0001-5972-3711
AD  - Certara Inc., Princeton, New Jersey.
AD  - School of Clinical Sciences, Faculty of Health, Queensland University of 
      Technology, Brisbane, QLD, Australia.
AD  - Institute of Pharmacy, Freie Universitat Berlin, Berlin, Germany.
FAU - Keane, Colm
AU  - Keane C
AUID- ORCID: 0000-0002-9009-9934
AD  - Mater Research Institute, The University of Queensland, Brisbane, QLD, Australia.
AD  - Haematology, Princess Alexandra Hospital, Woolloongabba, QLD, Australia.
FAU - Gandhi, Maher K
AU  - Gandhi MK
AUID- ORCID: 0000-0003-1000-5393
AD  - Mater Research Institute, The University of Queensland, Brisbane, QLD, Australia.
AD  - Haematology, Princess Alexandra Hospital, Woolloongabba, QLD, Australia.
LA  - eng
PT  - Case Reports
PT  - Research Support, Non-U.S. Gov't
DEP - 20210611
PL  - United States
TA  - Am J Transplant
JT  - American journal of transplantation : official journal of the American Society of 
      Transplantation and the American Society of Transplant Surgeons
JID - 100968638
RN  - 0 (Piperidines)
RN  - 1X70OSD4VX (ibrutinib)
RN  - JAC85A2161 (Adenine)
SB  - IM
MH  - Adenine/analogs & derivatives
MH  - Central Nervous System
MH  - *Epstein-Barr Virus Infections/complications/drug therapy
MH  - Herpesvirus 4, Human
MH  - Humans
MH  - *Lymphoma, Non-Hodgkin/drug therapy/etiology
MH  - *Lymphoproliferative Disorders/drug therapy/etiology
MH  - Piperidines
MH  - T-Lymphocytes
OTO - NOTNLM
OT  - cancer / malignancy / neoplasia: hematogenous / leukemia / lymphoma
OT  - complication: malignant
OT  - dialysis: hemodialysis
OT  - hematology / oncology
OT  - immunobiology
OT  - infection and infectious agents - viral: Epstein-Barr Virus (EBV)
OT  - translational research / science
EDAT- 2021/05/05 06:00
MHDA- 2021/10/21 06:00
CRDT- 2021/05/04 07:20
PHST- 2021/03/30 00:00 [revised]
PHST- 2021/01/27 00:00 [received]
PHST- 2021/04/23 00:00 [accepted]
PHST- 2021/05/05 06:00 [pubmed]
PHST- 2021/10/21 06:00 [medline]
PHST- 2021/05/04 07:20 [entrez]
AID - S1600-6135(22)08767-6 [pii]
AID - 10.1111/ajt.16628 [doi]
PST - ppublish
SO  - Am J Transplant. 2021 Oct;21(10):3465-3471. doi: 10.1111/ajt.16628. Epub 2021 Jun 
      11.